Technetium-99 m d , l-HM-PAO : A New Rathopharmaceutical for SPECT Imaging of Regional CerebralBlood Perfusion

Following investigation of a large number of new ligands based upon propylene amine oxime (PnAO) the d,l-diastereoisomer of hexamethyl propyleneamine oxime (HM-PAO) was selected as the preferred ligand for 99mTc as a tracer for cerebral perfusion imaging. The neutral, lipophilic 99mTc complex of d,l-HM-PAO was formed in high yield by stannous reduction of 99Mo/99mTc generator eluate using a kit formulation of the ligand. Two minutes following i.v. administration of this complex in rats, 2.25% of the injected dose appears in the brain. Little washout of the tracer is observed up to 24 hr postinjection. By qualitative autoradiographic comparison with iodoantipyrine this new radiopharmaceutical displays blood flow dependent brain uptake with little redistribution of the tracer over time. The lipophilic 99mTc complex converts slowly in vitro to a secondary complex. This conversion process may account for the ability of [99mTc]d,l-HM-PAO to be retained within the brain without redistribution.

[1]  H N Wagner,et al.  Design, preparation, and biodistribution of a technetium-99m triaminedithiol complex to assess regional cerebral blood flow. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  B. Holman,et al.  A comparison of two cerebral perfusion tracers, N-isopropyl I-123 p-iodoamphetamine and I-123 HIPDM, in the human. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  R. Murmann,et al.  Oxo[3,3'‐(1,3‐propanediyldiimino)bis(3‐methyl‐2‐butanone oximato)(3–)‐N,N',N'',N''']technetium(V), [TcO(C13H25N4O2)] , 1984 .

[4]  Ws Snyder,et al.  MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs , 1975 .

[5]  H. Kung,et al.  Regional intracellular pH shift: a proposed new mechanism for radiopharmaceutical uptake in brain and other tissues. , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  B L Holman,et al.  Biodistribution and dosimetry of N-isopropyl-p-[123I]iodoamphetamine in the primate. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  R. A. Holmes,et al.  Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging , 1985, Nuclear medicine communications.

[8]  R. Baldwin,et al.  Development of I-123-labeled amines for brain studies: localization of I-123 iodophenylalkyl amines in rat brain. , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  D. Nowotnik,et al.  Synthesis, characterization, and x-ray structural determinations of technetium(V)-oxo-tetradentate amine oxime complexes , 1986 .

[10]  H. Kung,et al.  RADIOIODINE-LABELED N,N-DIMETHYL-N′-(2-HYDROXY-3-ALKYL-5-IODOBENZYL)-1,3-PROPANEDIAMINES FOR BRAIN PERFUSION IMAGING , 1983 .

[11]  P. Ell,et al.  Development of a Lipophilic 99mTc Complex Useful for Brain Perfusion Evaluation with Conventional SPECT Imaging Equipment , 1986 .

[12]  R. A. Holmes,et al.  A neutral lipophilic complex of 99mTc with a multidentate amine oxime. , 1984, The International journal of applied radiation and isotopes.

[13]  H. Kung,et al.  Radioiodine-labeled N,N-dimethyl-N'-(2-hydroxy-3-alkyl-5-iodobenzyl)-1,3-propanediamines for brain perfusion imaging. , 1983, Journal of medicinal chemistry.

[14]  R. A. Holmes,et al.  The behavior of neutral amine oxime chelates labelled with Tc at tracer level. , 1984, International Journal of Nuclear Medicine and Biology.